Oxprenolol in Parkinson's disease.
D000433:1-Propanol / Q000009:adverse effects / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D000605:Amino Alcohols / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005059:Euphoria / Q000139:chemically induced; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D013565:Sympatholytics / Q000627:therapeutic use*; D014202:Tremor / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D010919:Placebos; D011437:Propylamines; D013565:Sympatholytics; D000433:1-Propanol